Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

124.86 +1.57 (+1.27%)
Streaming Delayed Price Updated: 2:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 766,890
Open 123.27
Bid (Size) 124.77 (7)
Ask (Size) 124.92 (7)
Prev. Close 123.29
Today's Range 122.37 - 126.13
52wk Range 108.63 - 157.98
Shares Outstanding 101,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals. 
Via Chartmill
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga

Performance

YTD
-5.22%
-5.22%
1 Month
+7.11%
+7.11%
3 Month
-17.25%
-17.25%
6 Month
-10.45%
-10.45%
1 Year
+13.91%
+13.91%

More News

Read More
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
Via The Motley Fool
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Via Chartmill
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
Via Chartmill
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Via Benzinga
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Via Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Neurocrine Biosciences Stock Was Tumbling This Week
Via The Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Via Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.